Scotia
Article Abstract:
Scotia is active in lipid biology, obesity, drug delivery and cancer therapies. The company's biggest stockholder is Perpetual, which has acquired over 5 million stocks from the founder, David Horrobin, who has ceased to be chief executive. The company's product, Foscan, is in advanced stages of trials. The company has also signed an agreement with General Foods for its anti-obesity product, Olibra, and progress is reportedly being made in its drug delivery operations.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Miracle drugs, mega profits
Article Abstract:
The rapid progress being made in medical research means that many firms are now developing wonder-drugs which could transform the companies and make them huge profits. Promising areas include central nervous system drugs and stem cell research.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Bayer reviews pharma strategy
Article Abstract:
Chemicals and pharmaceuticals firm Bayer is to review its drugs strategy, with a joint venture thought to be the most likely outcome. Bayer has been badly hit by deaths linked to its anti-cholesterol drug Baycol.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Courtaulds. Threadbare demerger plan. Talent is not enough
- Abstracts: Network wars. Barcrest Group's many games for UK players
- Abstracts: Cordiant bids adieu. Mythical aegis of takeovers
- Abstracts: Costly compliance. Best developed market banks. Getting Back to Basics
- Abstracts: Specialty pharmaceuticals. Drug delivery stocks